ProMIS Neurosciences Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
PMN$3.98-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(expressed in US dollars)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Nine Months Ended · | |||||||
| · · September 30, · | |||||||
| · 2025 · 2024 · | |||||||
| Cash flows from operating activities | | | | | | | |
| Net (loss) income | | $(29,045,059) | | $3,017,080 | | ||
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | | | | | | | |
| Share-based compensation expense | | 654,457 | | 202,619 | | ||
| Loss on issuance of common shares, warrants, and pre-funded warrants in July 26, 2024 PIPE | | | — | | | 3,494,536 | |
| Change in fair value of financial instruments | | — | | (17,014,080) | | ||
| Changes in operating assets and liabilities: | | | | | |||
| Prepaid expenses and other current assets | | (438,693) | | (1,452,638) | | ||
| Accounts payable | | 2,474,022 | | (6,267,901) | | ||
| Accrued liabilities | | 7,518,600 | | (446,674) | | ||
| Net cash used in operating activities | | (18,836,673) | | (18,467,058) | | ||
| | | | | | | | |
| Cash flows from financing activities | | | | ||||
| Proceeds from issuance of Common Shares pursuant to ATM offering, net of issuance costs | | | 708,468 | | | 190,274 | |
| Proceeds from issuance of pre-funded warrants from July 22, 2025 Registered Direct Offering, net of issuance costs | | | 697,658 | | | | |
| Proceeds from issuance of Common Shares and warrants from July 22, 2025 discounted warrant exercise and PIPE, net of issuance costs | | 8,391,027 | | — | | ||
| Proceeds from issuance of Common Shares and warrants from July 28, 2025 discounted warrant exercise and PIPE, net of issuance costs | | 11,144,468 | | — | | ||
| Proceeds from issuance of Common Shares, pre-funded warrants, and accompanying warrants from July 26, 2024 PIPE, net of issuance costs | | | — | | | 27,187,497 | |
| Proceeds from exercise of pre-funded warrants | | 3,050 | | 28,039 | | ||
| Net cash provided by financing activities | | 20,944,671 | | 27,405,810 | | ||
| | | | | | | | |
| Net increase in cash | | 2,107,998 | | 8,938,752 | | ||
| | | | | | | | |
| Cash at beginning of period | | 13,291,167 | | 12,598,146 | | ||
| Cash at end of period | | $15,399,165 | | $21,536,898 | | ||
| | | | | | | | |
| Noncash financing activities | | | | ||||
| Subscription receivable from July 26, 2024 PIPE | | $— | | $500,000 | | ||
| (Decrease) increase in share-based compensation liability on CAD denominated share options (increasing) decreasing additional paid-in-capital | | $(145,110) | | $81,912 | | ||
| July 22, 2025 deferred discount for fair value modification of warrants | | $930,841 | | $— | | ||
| July 22, 2025 deferred discount issuance cost recognized on completion of PIPE | | $(930,841) | | $— | | ||
| July 28, 2025 deferred discount for fair value modification of warrants | | $1,794,146 | | $— | | ||
| July 28, 2025 deferred discount issuance cost recognized on completion of PIPE | | $(1,794,146) | | $— | | ||
| | | | | | | | |
| Supplemental disclosure of cash flow information | | | | | | | |
| Cash paid for interest | | $— | | $76,775 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.